株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鬱血性心不全(心不全):パイプライン製品の分析

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 245973
出版日 ページ情報 英文 364 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
鬱血性心不全(心不全):パイプライン製品の分析 Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017
出版日: 2017年03月15日 ページ情報: 英文 364 Pages
概要

鬱血性心不全は心不全は鬱血性心不全(CHF)としても知られています。CHFは、心臓がもはや酸素を豊富に含む血液を十分に送り出すことが出来ない状態です。症状には、咳、疲労感、虚弱、脱力感、食欲不振、肝臓または腹部の腫れ(肥大)、足・足首の腫れ、および体重増加などがあります。発病の要因には、高血圧、糖尿病、睡眠時無呼吸、アルコール摂取および不整脈が含まれます。治療には、外科手術、血管拡張剤、ベータブロッカー、および利尿薬などが用いられます。

当レポートでは、世界における鬱血性心不全治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 調査範囲

鬱血性心不全(心不全)の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Araim Pharmaceuticals, Inc.
  • ARCA biopharma, Inc.
  • Ascelegen Therapeutics, Inc.
  • Asterias Biotherapeutics, Inc.
  • Athersys, Inc.
  • Bayer AG
  • BEAT BioTherapeutics Corp.
  • BioCardia, Inc.
  • Bristol-Myers Squibb Company
  • Capricor Therapeutics, Inc.
  • Cell Therapy Limited
  • Celyad SA
  • Eli Lilly and Company
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • Heart Metabolics Limited
  • Hemostemix Ltd
  • Innopharmax Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Juventas Therapeutics, Inc.
  • La Jolla Pharmaceutical Company
  • Laboratoires Pierre Fabre SA
  • Lead Discovery Center GmbH
  • Lee's Pharmaceutical Holdings Limited
  • Les Laboratoires Servier SAS
  • Lonestar Heart, Inc.
  • Mast Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mesoblast Limited
  • miRagen Therapeutics, Inc.
  • MorphoSys AG
  • NanoCor Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Nuo Therapeutics, Inc.
  • 小野薬品工業
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • PharmaIN Corporation
  • PhaseBio Pharmaceuticals, Inc.
  • Pluristem Therapeutics Inc.
  • Quantum Genomics SA
  • Recardio GmbH
  • RedHill Biopharma Ltd.
  • Renova Therapeutics Inc
  • scPharmaceuticals Inc
  • Stealth BioTherapeutics Inc.
  • Stemedica Cell Technologies, Inc.
  • Target Heart Biotec Srl
  • Theravance Biopharma, Inc.
  • TiGenix NV
  • Torrent Pharmaceuticals Limited
  • Trevena, Inc.
  • U.S. Stem Cell, Inc.
  • Vichem Chemie Research Ltd.
  • Vicore Pharma AB
  • Zensun (Shanghai) Sci & Tech Co., Ltd.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9049IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 28, 16, 2, 32, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 19 and 8 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 7
  • List of Figures 9
  • Introduction 10
  • Global Markets Direct Report Coverage 10
  • Congestive Heart Failure (Heart Failure) - Overview 11
  • Congestive Heart Failure (Heart Failure) - Therapeutics Development 12
  • Pipeline Overview 12
  • Pipeline by Companies 13
  • Pipeline by Universities/Institutes 19
  • Products under Development by Companies 22
  • Products under Development by Universities/Institutes 29
  • Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 32
  • Assessment by Target 32
  • Assessment by Mechanism of Action 37
  • Assessment by Route of Administration 42
  • Assessment by Molecule Type 44
  • Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 46
  • Allosteros Therapeutics Inc 46
  • Amgen Inc 46
  • Anexon Inc 47
  • AnGes MG Inc 47
  • Araim Pharmaceuticals Inc 48
  • Arbor Pharmaceuticals LLC 48
  • Ascelegen Therapeutics Inc 49
  • AstraZeneca Plc 49
  • Athersys Inc 50
  • Bayer AG 50
  • BEAT BioTherapeutics Corp 51
  • BioCardia Inc 51
  • Boehringer Ingelheim GmbH 52
  • Bristol-Myers Squibb Company 52
  • Capricor Therapeutics Inc 53
  • Celixir Ltd 53
  • Celyad SA 54
  • Daiichi Sankyo Company Ltd 54
  • F. Hoffmann-La Roche Ltd 55
  • FibroGen Inc 55
  • GlaxoSmithKline Plc 56
  • Heart Metabolics Ltd 56
  • Hemostemix Ltd 57
  • Innopharmax Inc 57
  • Intrexon Corp 58
  • Jiangsu Hengrui Medicine Co Ltd 58
  • Juventas Therapeutics Inc 59
  • La Jolla Pharmaceutical Company 59
  • Lead Discovery Center GmbH 60
  • Lee's Pharmaceutical Holdings Ltd 60
  • Les Laboratoires Servier SAS 61
  • Lonestar Heart Inc 61
  • Madeleine Pharmaceuticals Inc 62
  • Mast Therapeutics Inc 62
  • Merck & Co Inc 63
  • Mesoblast Ltd 63
  • MorphoSys AG 64
  • NanoCor Therapeutics Inc 64
  • Neurocrine Biosciences Inc 65
  • Novartis AG 65
  • Nuo Therapeutics Inc 66
  • Nyken BV 66
  • Orion Oyj 67
  • Palatin Technologies Inc 67
  • PharmaIN Corp 68
  • PhaseBio Pharmaceuticals Inc 68
  • Quantum Genomics SA 69
  • Recardio GmbH 69
  • RedHill Biopharma Ltd 70
  • Renova Therapeutics Inc 70
  • scPharmaceuticals Inc 71
  • Stealth BioTherapeutics Inc 71
  • Stemedica Cell Technologies Inc 72
  • Target Heart Biotec Srl 72
  • Theravance Biopharma Inc 73
  • TiGenix NV 73
  • Torrent Pharmaceuticals Ltd 74
  • Trevena Inc 74
  • U.S. Stem Cell Inc 75
  • Vicore Pharma AB 75
  • Zensun (Shanghai) Sci & Tech Co Ltd 76
  • Congestive Heart Failure (Heart Failure) - Drug Profiles 77
  • (hydralazine + isosorbide dinitrate) XR - Drug Profile 77
  • (sacubitril + valsartan) - Drug Profile 78
  • AAVS-100A1 - Drug Profile 85
  • ACP-01 - Drug Profile 87
  • AdipoCell - Drug Profile 90
  • AE-07 - Drug Profile 93
  • AK-10 - Drug Profile 94
  • aladorian sodium - Drug Profile 95
  • ALD-201 - Drug Profile 97
  • AMG-986 - Drug Profile 99
  • AntimiR-199a - Drug Profile 100
  • Antisense RNAi Gene Therapy to Inhibit ANGPTL2 for Heart Failure - Drug Profile 101
  • ANX-042 - Drug Profile 102
  • ARX-720 - Drug Profile 103
  • AZD-4831 - Drug Profile 104
  • BAY-1753011 - Drug Profile 105
  • BAY-868050 - Drug Profile 106
  • BBR-12 - Drug Profile 107
  • beperminogene perplasmid - Drug Profile 108
  • BMS-986231 - Drug Profile 114
  • C-21 - Drug Profile 116
  • C-Cure - Drug Profile 119
  • CAP-1002 - Drug Profile 125
  • Carfostin - Drug Profile 131
  • carvedilol CR - Drug Profile 132
  • carvedilol phosphate CR - Drug Profile 134
  • Cell Therapy for Heart failure - Drug Profile 135
  • cenderitide - Drug Profile 136
  • cibinetide - Drug Profile 140
  • CLR-325 - Drug Profile 143
  • CTX-101 - Drug Profile 144
  • dapagliflozin propanediol - Drug Profile 146
  • Drug to Inhibit Calpain for Right Heart Failure - Drug Profile 153
  • Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 154
  • ECRA-1 - Drug Profile 155
  • elamipretide - Drug Profile 156
  • empagliflozin - Drug Profile 164
  • enalapril maleate - Drug Profile 173
  • FG-6874 - Drug Profile 174
  • furosemide - Drug Profile 175
  • GDF-11 - Drug Profile 177
  • Gene Therapy for Heart Failure - Drug Profile 178
  • Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile 179
  • Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile 180
  • Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile 181
  • Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 182
  • Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 183
  • Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile 184
  • GSK-2798745 - Drug Profile 185
  • istaroxime - Drug Profile 186
  • ITD-1 - Drug Profile 188
  • ivabradine hydrochloride - Drug Profile 189
  • ivabradine hydrochloride SR - Drug Profile 192
  • JVS-100 - Drug Profile 193
  • K-1062 - Drug Profile 198
  • KBP-5074 - Drug Profile 199
  • L-2286 - Drug Profile 201
  • levosimendan - Drug Profile 202
  • milrinone ER - Drug Profile 207
  • Monoclonal Antibody to Activate Sodium Potassium ATPase for Congestive Heart Failure and Status Epilepticus - Drug Profile 208
  • Monoclonal Antibody to Inhibit Periostin1 for Congestive Heart Failure - Drug Profile 209
  • MP-3167 - Drug Profile 210
  • MPC-150IM - Drug Profile 211
  • MRS-2339 - Drug Profile 216
  • MyoCell - Drug Profile 217
  • MyoCell SDF-1 - Drug Profile 219
  • NBI-69734 - Drug Profile 220
  • neladenoson bialanate - Drug Profile 221
  • Neucardin - Drug Profile 222
  • NM-922 - Drug Profile 225
  • NP-202 - Drug Profile 226
  • NPA-7 - Drug Profile 228
  • NYK-1112 - Drug Profile 229
  • Oligonucleotides to Antagonise Beta 1 Adrenergic Receptor for Pediatric Heart Failure - Drug Profile 230
  • omecamtiv mecarbil MR - Drug Profile 231
  • PB-1046 - Drug Profile 239
  • Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 241
  • Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 242
  • perhexiline maleate - Drug Profile 243
  • PF-05285401 - Drug Profile 245
  • PHIN-1138 - Drug Profile 257
  • pirfenidone - Drug Profile 258
  • PL-3994 - Drug Profile 265
  • PL-5028 - Drug Profile 267
  • poloxamer - Drug Profile 268
  • pyroglutaminated serpinin - Drug Profile 270
  • QGC-101 - Drug Profile 271
  • REC-02 - Drug Profile 272
  • Recombinant Protein for Congestive Heart Failure - Drug Profile 273
  • ROMKi-B - Drug Profile 274
  • RT-100 - Drug Profile 275
  • RT-110 - Drug Profile 277
  • RT-300 - Drug Profile 278
  • RT-400 - Drug Profile 279
  • S-38844 - Drug Profile 280
  • serelaxin - Drug Profile 281
  • serpinin - Drug Profile 286
  • SG-1002 - Drug Profile 287
  • Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 288
  • Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile 289
  • Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 290
  • Small Molecules for Diastolic Heart Failure - Drug Profile 291
  • Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 292
  • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 293
  • Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 294
  • Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 295
  • Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile 296
  • Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 297
  • Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 298
  • Small molecules to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure, Breast Cancer and Chronic Obstructive Pulmonary Disease - Drug Profile 299
  • Small Molecules to Inhibit Porcupine for Oncology, Degenerative Disorders And Congestive Heart Failure - Drug Profile 300
  • Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 301
  • Small Molecules to Target Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 302
  • sodium nitrite - Drug Profile 303
  • SP-20202 - Drug Profile 307
  • Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 308
  • Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 314
  • Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 315
  • Stem Cell Therapy for Heart Failure - Drug Profile 316
  • Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 317
  • Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 318
  • Synthetic Peptide to Agonize Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile 319
  • Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile 320
  • TD-0714 - Drug Profile 321
  • TD-1439 - Drug Profile 323
  • TR-4 - Drug Profile 324
  • TRC-4186 - Drug Profile 325
  • TRV-120023 - Drug Profile 327
  • ularitide - Drug Profile 328
  • valsartan CR - Drug Profile 330
  • VCP-746 - Drug Profile 331
  • vericiguat - Drug Profile 332
  • Xcel-hCardP - Drug Profile 334
  • Congestive Heart Failure (Heart Failure) - Dormant Projects 335
  • Congestive Heart Failure (Heart Failure) - Discontinued Products 341
  • Congestive Heart Failure (Heart Failure) - Product Development Milestones 343
  • Featured News & Press Releases 343
  • Appendix 354
  • Methodology 354
  • Coverage 354
  • Secondary Research 354
  • Primary Research 354
  • Expert Panel Validation 354
  • Contact Us 354
  • Disclaimer 355

List of Tables

  • Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Allosteros Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Anexon Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Arbor Pharmaceuticals LLC, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by AstraZeneca Plc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Athersys Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Celixir Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Intrexon Corp, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Madeleine Pharmaceuticals Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Nyken BV, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Orion Oyj, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corp, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Trevena Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell Inc, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2017
  • Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2017
  • Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top